Targeting mutation slows breast cancer spread, study finds

Credit: Pixabay/CC0 Public Domain
The progression of certain types of breast cancers can be slowed by identifying a particular genetic mutation and then quickly adapting treatment, a first-of-its-kind study showed on Friday.

Breast cancer tumour cells change over time, and sometimes cause mutations that are resistant to the drugs the are taking.

For the new study, which was published in the journal Lancet Oncology, the French-led researchers targeted a mutation in the blood called bESR1mut.

To identify the mutation, the researchers used a promising, relatively new technique called a liquid biopsy.

It is able to analyse the contents of tumours without needing a sample of breast tissue, which is normally obtained via a far more invasive traditional biopsy.

In this case, the researchers used the liquid biopsy to sample the blood of advanced patients to see if they could spot the bESR1mut mutation.

Out of more than a thousand across 83 hospitals in France, the researchers found that around a quarter had seen bESR1mut increase in their blood.

Around 170 of those patients were split into two groups.

One group continued with their current treatment, while the other was switched to a regime that included fulvestrant, a hormone drug which previous research suggested could target mutations like bESR1mut.

The cancer in the patients taking fulvestrant stopped or progressed more slowly by a matter of several months compared to the , the study found.

The researchers said it was "the first prospective randomised trial showing that the early therapeutic targeting of bESR1mut results in significant clinical benefit".

Looking beyond bESR1mut, they said this technique—using a to find a mutation, then rapidly changing medication—could serve as model for future treatment regimes.

The study did have some limitations, including that it only examined a specific type of breast cancer in which the tumour is receptive to estrogen.

That made these tumours more susceptible to fulvestrant, which works by blocking estrogen's effect on .

Around 2.3 million women were diagnosed with breast cancer and 685,000 died worldwide in 2020 alone, according to the World Health Organization.

By the end of 2020, 7.8 million were living with breast cancer who had been diagnosed in the past five years, making it the world's most prevalent cancer, the WHO said.

Journal information: Lancet Oncology

© 2022 AFP

Citation: Targeting mutation slows breast cancer spread, study finds (2022, September 30) retrieved 8 December 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Next-generation liquid biopsy detects nano-sized signs of breast cancer in early-stage patients


Feedback to editors